(Q37462562)

20 August 2017

title

Side effects of long-term oral antiviral therapy for hepatitis B. (English)

1 reference

20 August 2017

Robert J Fontana

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

issue

5 Suppl

1 reference

20 August 2017

page(s)

S185-95

1 reference

Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides

20 August 2017

cites work

1 reference

Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis

21 January 2018

1 reference

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

21 January 2018

1 reference

7 January 2021

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

1 reference

7 January 2021

What is oxidative stress?

1 reference

7 January 2021

The mitochondrial DNA polymerase as a target of oxidative damage

1 reference

7 January 2021

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine

1 reference

7 January 2021

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

1 reference

7 January 2021

Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts

1 reference

7 January 2021

Mitochondrial dysfunction: patient monitoring and toxicity management

1 reference

7 January 2021

Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition

1 reference

7 January 2021

Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors

1 reference

7 January 2021

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study

1 reference

7 January 2021

Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.

1 reference

7 January 2021

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial

1 reference

7 January 2021

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial

1 reference

7 January 2021

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

1 reference

7 January 2021

Fanconi syndrome and renal failure induced by tenofovir: a first case report

1 reference

7 January 2021

Renal safety of tenofovir in HIV treatment-experienced patients.

1 reference

7 January 2021

1 reference

7 January 2021

Acute tubular necrosis in a patient receiving tenofovir

1 reference

7 January 2021

Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.

1 reference

7 January 2021

Antiviral drug-induced nephrotoxicity

1 reference

7 January 2021

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

7 January 2021

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

7 January 2021

Rhabdomyolysis due to Lamivudine administration in a liver transplant recipient

1 reference

7 January 2021

Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage.

1 reference

7 January 2021

Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?

1 reference

7 January 2021

Exacerbation of peripheral neuropathy by lamivudine

1 reference

7 January 2021

Lamivudine-induced muscle mitochondrial toxicity.

1 reference

7 January 2021

Lamivudine-associated macrocytosis in HIV-infected patients

1 reference

7 January 2021

Management of patients with decompensated HBV cirrhosis

1 reference

7 January 2021

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

7 January 2021

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

7 January 2021

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

1 reference

7 January 2021

Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion

1 reference

7 January 2021

Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir

1 reference

7 January 2021

Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency

1 reference

7 January 2021

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

7 January 2021

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.

1 reference

7 January 2021

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

1 reference

7 January 2021

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

7 January 2021

Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients

1 reference

7 January 2021

Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge

1 reference

7 January 2021

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

7 January 2021

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

1 reference

7 January 2021

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

7 January 2021

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

1 reference

7 January 2021

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

1 reference

7 January 2021

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

7 January 2021

Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.

1 reference

7 January 2021

The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy

1 reference

7 January 2021

The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients

1 reference

7 January 2021

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

7 January 2021

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children

1 reference

7 January 2021

Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

1 reference

7 January 2021

Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade

1 reference

7 January 2021

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

1 reference

7 January 2021

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

1 reference

7 January 2021

Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy

1 reference

7 January 2021

Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy

1 reference

7 January 2021

Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors

1 reference

7 January 2021

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection

1 reference

7 January 2021

Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy.

1 reference

7 January 2021

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.

1 reference

7 January 2021

Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy

1 reference

7 January 2021

Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy

1 reference

7 January 2021

Mitochondrial dysfunction following perinatal exposure to nucleoside analogues

1 reference

7 January 2021

In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22885

1 reference

20 August 2017

1 reference